Since NLRP3 inflammasome appears to be a key molecular link in the PD inflammatory pathway, targeting selectively NLRP3/Cas-1 pathway with small molecule inhibitors can represent a valid approach for treating neuroinflammatory diseases. This evidence concerns the gene NLRP3 and Parkinson disease.